#USA #Veeva Systems #Pleasanton #Vault CRM #Gilead Sciences

Gilead Sciences Expands Partnership with Veeva Vault CRM

In an exciting development for the pharmaceutical industry, Gilead Sciences has announced its commitment to Veeva Vault CRM, a significant move that reinforces its long-standing relationship with Veeva Systems. This partnership stands to elevate the way Gilead operates in commercial execution, fostering innovation through advanced software solutions.

Veeva Systems (NYSE: VEEV) made the announcement on September 10, 2025, highlighting Gilead's reputation as a pioneer in life-changing medicines and its contributions to scientific advancements in areas such as virology, inflammation, and oncology. Peter Gassner, CEO of Veeva, expressed his enthusiasm about the collaboration, stating, "We are honored to be a strategic partner to Gilead and extend that partnership to Vault CRM."

Anna Åsberg, the global CIO of Gilead Sciences, also shared her excitement about the project, emphasizing the shared commitment between the two organizations to advance medicine. "We are excited to expand our long-standing partnership with Veeva by moving to Vault CRM. We share a deep commitment to advancing medicine and are excited to explore the potential of Veeva AI to help drive commercial execution to the next level."

What is Veeva Vault CRM?

Vault CRM is an integral part of the Veeva Vault CRM Suite, designed to optimize commercial execution. This suite of applications is built with high-level capabilities, including agentic AI functions, which enhance efficiency and effectiveness in engagements. Notably, Veeva AI for Vault CRM offers features such as pre-call planning, compliant free text generation, and voice control functionalities. These advancements will undoubtedly provide Gilead with a stronger footing in the competitive biopharmaceutical landscape.

For over three decades, Gilead Sciences has been at the forefront of breakthroughs in medicine, from pioneering treatments for HIV to addressing life-threatening diseases like viral hepatitis, COVID-19, and various cancers. With operations in over 35 countries, Gilead aims to create a healthier planet through innovative approaches to healthcare.

Veeva Systems itself has carved out a notable niche within the life sciences sector, providing a comprehensive cloud solution combining software, data, and business consulting. Currently serving more than 1,500 clients, Veeva seeks to balance stakeholder interests, offering a robust infrastructure crucial for the pharmaceutical industry’s future. As a Public Benefit Corporation, Veeva remains dedicated to enhancing the end-to-end process of vaccine and drug development, which is increasingly required in today's evolving health landscape.

Looking Ahead

The transition to Vault CRM is set against a backdrop of increasing demand for streamlined operations in the pharmaceutical sector. The potential for AI implementation within Gilead's commercial strategies may herald new ways of reaching and treating patients effectively. From the insights gained through data analysis to the AI-driven recommendations during sales interactions, Gilead's adoption of Veeva Vault CRM marks a significant point in the evolution of pharmaceutical customer relationship management.

As the industry continues to push the boundaries of research and patient care, partnerships like the one between Gilead Sciences and Veeva Systems will likely drive forward innovations that empower healthcare professionals and enhance patient outcomes. By harnessing advanced technology with a patient-centered focus, Gilead aims to continue its legacy of healthcare improvement through meaningful advancements in treatment and medicine.

For further information about Veeva Systems and their offerings, visit their official website at veeva.com.